PharMerica Corp. (NYSE:PMC) saw an uptick in trading volume on Friday . 265,702 shares traded hands during trading, an increase of 80% from the previous session’s volume of 147,530 shares.The stock last traded at $26.54 and had previously closed at $26.31.

Several research firms have weighed in on PMC. Zacks Investment Research upgraded shares of PharMerica Corp. from a “sell” rating to a “hold” rating in a research report on Tuesday, May 3rd. Barrington Research reiterated an “outperform” rating and set a $34.00 price objective (up from $30.00) on shares of PharMerica Corp. in a research report on Tuesday, May 10th. Bank of America Corp. began coverage on shares of PharMerica Corp. in a research report on Tuesday, June 7th. They set a “buy” rating and a $32.00 price objective on the stock. Finally, TheStreet cut shares of PharMerica Corp. from a “buy” rating to a “hold” rating in a research report on Monday, May 9th. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $31.57.

The stock’s 50 day moving average is $25.39 and its 200-day moving average is $25.41. The firm has a market capitalization of $816.30 million and a price-to-earnings ratio of 27.67.

PharMerica Corp. (NYSE:PMC) last issued its earnings results on Friday, May 6th. The company reported $0.45 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.43 by $0.02. The firm earned $524.50 million during the quarter, compared to the consensus estimate of $509.45 million. During the same period in the previous year, the company posted $0.48 EPS. The firm’s revenue for the quarter was up 2.5% on a year-over-year basis. On average, equities research analysts forecast that PharMerica Corp. will post $2.02 earnings per share for the current year.

Several large investors recently modified their holdings of PMC. Airain ltd increased its stake in shares of PharMerica Corp. by 8,998.1% in the fourth quarter. Airain ltd now owns 1,222,061 shares of the company’s stock valued at $14,499,000 after buying an additional 1,208,629 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of PharMerica Corp. by 1.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,579,111 shares of the company’s stock valued at $90,269,000 after buying an additional 41,387 shares in the last quarter. Redwood Investments LLC increased its stake in shares of PharMerica Corp. by 6.3% in the fourth quarter. Redwood Investments LLC now owns 58,400 shares of the company’s stock valued at $2,044,000 after buying an additional 3,444 shares in the last quarter. Trexquant Investment LP increased its stake in shares of PharMerica Corp. by 148.9% in the fourth quarter. Trexquant Investment LP now owns 30,140 shares of the company’s stock valued at $1,055,000 after buying an additional 18,031 shares in the last quarter. Finally, Systematic Financial Management LP increased its stake in shares of PharMerica Corp. by 12.0% in the fourth quarter. Systematic Financial Management LP now owns 486,036 shares of the company’s stock valued at $17,011,000 after buying an additional 51,887 shares in the last quarter.

PharMerica Corporation is an institutional pharmacy services company. The Company services healthcare facilities, provides pharmacy management services to hospitals, provides specialty infusion services to patients outside a hospital setting and offers the national oncology pharmacy in the United States.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.